Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

NCT02633527 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

DRUG: Placebo
DRUG: 100mg SPN-812
DRUG: 200mg SPN-812
DRUG: 300mg SPN-812
DRUG: 400mg SPN-812

Sponsor

Supernus Pharmaceuticals, Inc.